Depolan (Morphine Sulfate Extended-Release)
Strong opioid analgesic for severe chronic pain – extended-release tablet
Quick Facts About Depolan
Key Takeaways About Depolan
- Extended-release formulation: Depolan provides sustained pain relief over approximately 12 hours, allowing twice-daily dosing for continuous pain management
- Never crush or chew: The tablet must be swallowed whole – breaking, crushing, or chewing releases the full dose at once, risking fatal overdose
- Risk of dependence: Morphine carries a risk of physical dependence, tolerance, and addiction; it should only be used under close medical supervision
- Respiratory depression: The most serious risk is slowed or stopped breathing, especially when starting treatment or increasing the dose
- Gradual dose changes: Treatment should never be stopped suddenly – your doctor will taper the dose gradually to avoid withdrawal symptoms
What Is Depolan and What Is It Used For?
Depolan is a prescription extended-release tablet containing morphine sulfate, a strong opioid analgesic. It is used for the management of severe pain that requires continuous, around-the-clock opioid treatment, particularly cancer-related pain and other chronic severe pain conditions where non-opioid painkillers are insufficient.
Morphine is one of the oldest and most widely studied analgesics in medical history, first isolated from opium in the early 19th century. It remains the gold standard against which all other opioid analgesics are measured. The World Health Organization (WHO) includes morphine on its Model List of Essential Medicines, recognizing its critical role in pain management worldwide. Depolan harnesses this powerful analgesic in an extended-release formulation designed to provide steady, predictable pain relief over a prolonged period.
The extended-release technology in Depolan uses a controlled-release matrix that gradually releases morphine sulfate as the tablet passes through the gastrointestinal tract. This means that instead of the rapid peak and trough pattern seen with immediate-release morphine (which requires dosing every 4–6 hours), Depolan maintains more consistent blood levels of morphine over approximately 12 hours. This steady-state pharmacokinetic profile translates to more uniform pain control with fewer periods of breakthrough pain and fewer episodes of dose-related side effects.
Depolan is primarily indicated for patients who require strong opioid analgesia for conditions such as moderate-to-severe cancer pain, severe post-operative pain during the transition from parenteral to oral opioids, and severe chronic non-cancer pain when other analgesics (including non-opioid medications and weaker opioids) have proven inadequate. It is not intended for mild or intermittent pain, nor for use as an as-needed analgesic. The decision to prescribe Depolan should be based on an individualized assessment of the patient's pain, overall medical condition, and treatment history.
How Morphine Works
Morphine is classified as a full agonist at the mu-opioid receptor (MOR), the primary receptor responsible for opioid-mediated analgesia. When morphine binds to mu-opioid receptors in the central nervous system – particularly in the brain and spinal cord – it triggers a cascade of intracellular signaling events that ultimately reduce the perception and emotional response to pain.
At the spinal level, morphine inhibits the release of excitatory neurotransmitters (such as substance P and glutamate) from primary afferent nociceptive fibers in the dorsal horn. This reduces the transmission of pain signals ascending to the brain. Simultaneously, morphine activates descending inhibitory pain pathways from the periaqueductal gray matter and rostral ventromedial medulla, which project downward to further suppress pain signaling in the spinal cord. The combined effect of these actions is a powerful reduction in both the intensity and unpleasantness of pain.
Beyond analgesia, morphine's interaction with opioid receptors throughout the body produces a range of additional pharmacological effects, including sedation, euphoria, respiratory depression, suppression of the cough reflex, pupillary constriction (miosis), and reduced gastrointestinal motility (leading to constipation). Many of these effects are dose-dependent and play an important role in both the therapeutic use and the side effect profile of the drug.
The World Health Organization's three-step analgesic ladder recommends strong opioids like morphine as Step 3 treatment for moderate to severe pain that does not respond adequately to non-opioid analgesics (Step 1) or weak opioids (Step 2). Morphine is considered the reference strong opioid for cancer pain management according to WHO, ESMO, and NCCN guidelines.
What Should You Know Before Taking Depolan?
Before taking Depolan, your doctor must assess your pain condition, medical history, and current medications. You must not take Depolan if you have severe respiratory depression, acute or severe bronchial asthma, known hypersensitivity to morphine, or paralytic ileus. Special caution is required in elderly patients, those with liver or kidney impairment, and patients with a history of substance use disorders.
Starting treatment with a strong opioid like Depolan is a significant clinical decision that requires careful evaluation by a healthcare professional. Your doctor will consider the nature and severity of your pain, previous treatments you have tried, your overall health status, and any factors that may increase your risk of side effects or complications. It is essential that you provide your doctor with a complete medical history and a list of all medications, supplements, and herbal products you are currently taking.
Contraindications
You must not take Depolan if any of the following apply to you:
- Severe respiratory depression: Conditions where breathing is already significantly impaired, as morphine further suppresses the respiratory drive
- Acute or severe bronchial asthma: In an unmonitored setting or without resuscitative equipment, morphine can worsen bronchospasm and respiratory failure
- Known hypersensitivity: Allergy to morphine sulfate or any of the excipients in the tablet formulation
- Paralytic ileus: A condition where the bowel is not moving; morphine further reduces gut motility and can cause dangerous complications
- Concurrent MAO inhibitor use: Use of monoamine oxidase inhibitors (MAOIs) within the past 14 days, due to risk of serotonin syndrome and unpredictable potentiation of morphine effects
- Acute alcoholism or delirium tremens: Morphine can worsen central nervous system depression and respiratory function in these patients
- Raised intracranial pressure or head injury: Morphine can elevate cerebrospinal fluid pressure and mask neurological deterioration
Warnings and Precautions
Talk to your doctor before taking Depolan if any of the following conditions apply to you:
- Chronic obstructive pulmonary disease (COPD): Even moderate doses of morphine can cause significant respiratory depression in patients with compromised lung function
- Elderly or debilitated patients: Increased sensitivity to opioids requires lower initial doses and more cautious dose titration
- Liver or kidney impairment: Reduced clearance of morphine and its active metabolite morphine-6-glucuronide (M6G) can lead to drug accumulation and increased toxicity
- Hypothyroidism or adrenal insufficiency: These endocrine conditions can increase sensitivity to opioid effects
- Prostatic hypertrophy or urethral stricture: Morphine can cause urinary retention
- Biliary tract disease or pancreatitis: Morphine may cause spasm of the sphincter of Oddi, worsening biliary colic
- Inflammatory bowel disease: Risk of toxic megacolon, particularly in ulcerative colitis
- History of seizures: Morphine can lower the seizure threshold
- History of substance use disorder: Patients with a personal or family history of alcohol or drug abuse are at increased risk of opioid misuse, abuse, and addiction
Pregnancy and Breastfeeding
Depolan should only be used during pregnancy if the potential benefit to the mother clearly outweighs the potential risk to the fetus. Morphine crosses the placenta, and prolonged use during pregnancy can cause neonatal opioid withdrawal syndrome (NOWS), a potentially life-threatening condition in the newborn characterized by irritability, excessive crying, tremors, feeding difficulties, diarrhea, and in severe cases, seizures. If opioid use is unavoidable during pregnancy, the lowest effective dose should be used for the shortest possible duration, and the newborn should be monitored for signs of withdrawal.
Morphine is excreted into breast milk in small amounts. At therapeutic doses, the amount transferred to the breastfed infant is generally considered low. However, neonates are particularly sensitive to opioids, and sedation or respiratory depression in the nursing infant is possible. Breastfeeding mothers taking Depolan should be advised to watch for signs of drowsiness, difficulty feeding, or breathing problems in their baby. If high doses are required or treatment is prolonged, an alternative feeding method may be advisable. Consult your doctor before breastfeeding while taking Depolan.
Serious, life-threatening, or fatal respiratory depression can occur with use of morphine, even when used as recommended. The risk is greatest during initiation of therapy or following a dose increase. Monitor closely, especially during the first 24–72 hours of treatment. Instruct patients and caregivers on how to recognize respiratory depression and to seek immediate medical attention if breathing becomes slow, shallow, or irregular.
How Does Depolan Interact with Other Drugs?
Depolan (morphine) has significant interactions with many medications. The most dangerous interactions are with benzodiazepines, other CNS depressants, and MAO inhibitors, which can cause fatal respiratory depression or serotonin syndrome. Always inform your doctor and pharmacist about all medications you take.
Drug interactions involving morphine can be broadly categorized into pharmacokinetic interactions (where another drug affects how morphine is absorbed, distributed, metabolized, or eliminated) and pharmacodynamic interactions (where another drug enhances or opposes morphine's effects in the body). Understanding these interactions is crucial for safe prescribing and patient safety. Below is a summary of the most clinically significant interactions.
Major Interactions
| Interacting Drug / Class | Effect | Clinical Recommendation |
|---|---|---|
| Benzodiazepines (e.g., diazepam, alprazolam, lorazepam) | Profound sedation, respiratory depression, coma, and death | Avoid concurrent use. If necessary, use lowest effective doses and shortest duration; monitor closely |
| MAO inhibitors (e.g., phenelzine, tranylcypromine, moclobemide) | Serotonin syndrome, hypertensive crisis, unpredictable potentiation of opioid effects | Contraindicated within 14 days of MAOI use |
| Other opioid analgesics | Additive respiratory depression and sedation | Calculate total opioid load carefully; adjust doses accordingly |
| Alcohol | Enhanced CNS depression; accelerated release of morphine from ER formulation possible | Avoid alcohol completely during treatment |
| Sedating antihistamines (e.g., promethazine, hydroxyzine) | Additive sedation and respiratory depression | Use with caution; consider non-sedating alternatives |
Minor Interactions
| Interacting Drug / Class | Effect | Clinical Recommendation |
|---|---|---|
| Rifampicin | Increased morphine metabolism via glucuronidation induction; reduced analgesic effect | Monitor pain control; dose adjustment may be needed |
| Cimetidine | May inhibit morphine metabolism, increasing plasma levels | Monitor for increased opioid effects |
| Anticholinergic drugs | Additive constipation and urinary retention | Prophylactic laxatives; monitor urinary function |
| Antihypertensives | Enhanced hypotensive effect | Monitor blood pressure, especially when standing |
| Muscle relaxants (e.g., baclofen, tizanidine) | Additive sedation and CNS depression | Use caution; reduce doses if necessary |
This is not an exhaustive list. Many other medications can interact with morphine. Always inform your doctor and pharmacist about all prescription and over-the-counter medications, vitamins, herbal products, and dietary supplements you are taking before starting Depolan. Do not start, stop, or change the dose of any medication without first consulting your healthcare provider.
What Is the Correct Dosage of Depolan?
The dosage of Depolan must be individualized based on the severity of pain, the patient's prior opioid exposure, and their response to treatment. For opioid-naive adults, the typical starting dose is 10 mg every 12 hours. The tablets must be swallowed whole and must never be crushed, chewed, or broken.
Opioid dosing is one of the most critical aspects of pain management. The goal is to achieve adequate pain relief while minimizing side effects. Because individual responses to morphine vary widely due to differences in genetics, body composition, organ function, pain type, and prior opioid exposure, there is no single correct dose for all patients. Dosing should be guided by clinical assessment and regular follow-up.
Adults
Opioid-Naive Adults
The recommended starting dose is 10 mg every 12 hours. This is the lowest available strength and represents an appropriate cautious starting point for patients who have not previously taken strong opioids. After assessing the patient's response over the first 48–72 hours, the dose may be adjusted upward in increments of no more than 25–50% to achieve satisfactory pain control.
Opioid-Experienced Adults (Conversion)
Patients converting from other opioids to Depolan should have their total daily opioid requirement calculated using established equianalgesic dose tables. Due to incomplete cross-tolerance between opioids, it is recommended to reduce the calculated equianalgesic dose by 25–50% when switching. The total daily morphine equivalent dose is then divided into two equal doses taken 12 hours apart.
Dose Titration
Dose adjustments should be made every 48 hours to allow steady-state plasma levels to be achieved. Increase the dose if pain is not adequately controlled, reduce the dose if side effects become troublesome. The principle of opioid titration is to find the lowest dose that provides acceptable pain relief with tolerable side effects.
Children
Depolan extended-release tablets are generally not recommended for children. Morphine dosing in pediatric patients requires careful weight-based calculation and is typically managed with liquid or immediate-release formulations that allow more precise dose adjustment. Any use of morphine in children should be under the direct supervision of a specialist experienced in pediatric pain management. The European Medicines Agency and the British National Formulary for Children provide specific dosing guidance for pediatric morphine use.
Elderly
Elderly patients (over 65 years) are generally more sensitive to the effects of opioids due to age-related changes in pharmacokinetics and pharmacodynamics. Renal function declines with age, leading to accumulation of the active metabolite morphine-6-glucuronide (M6G), which has significant analgesic and respiratory depressant activity. Starting doses should be reduced (typically 50% of the usual adult dose) and titration should proceed more slowly. Careful monitoring for excessive sedation, confusion, and respiratory depression is essential.
Missed Dose
If you miss a dose of Depolan, take it as soon as you remember. However, if it is almost time for your next scheduled dose (within approximately 4 hours), skip the missed dose and continue with your regular dosing schedule. Never take a double dose to make up for a missed one. Taking two doses close together significantly increases the risk of life-threatening respiratory depression. If you are unsure what to do, contact your doctor or pharmacist for guidance.
Overdose
Morphine overdose is a medical emergency that can be fatal. Symptoms include extreme drowsiness, pinpoint pupils (miosis), cold and clammy skin, slow or shallow breathing, loss of consciousness, and cardiovascular collapse. If overdose is suspected, call emergency services immediately. The specific antidote is naloxone (Narcan), an opioid receptor antagonist that can rapidly reverse respiratory depression. Multiple doses of naloxone may be required because morphine's duration of action, particularly in extended-release formulations, exceeds that of naloxone. The patient must be monitored for an extended period even after naloxone administration.
| Patient Group | Starting Dose | Frequency | Special Considerations |
|---|---|---|---|
| Opioid-naive adults | 10 mg | Every 12 hours | Titrate cautiously; reassess within 48–72 hours |
| Opioid-experienced adults | Based on conversion | Every 12 hours | Reduce calculated dose by 25–50% for cross-tolerance |
| Elderly (≥65 years) | 5–10 mg (reduced) | Every 12 hours | Slower titration; monitor M6G accumulation |
| Renal impairment | Reduced dose | Every 12 hours or extended | M6G accumulates; consider dose reduction or longer intervals |
| Hepatic impairment | Reduced dose | Every 12 hours | Impaired glucuronidation; increased bioavailability |
| Children | Not recommended | N/A | Use liquid/IR formulations under specialist supervision |
What Are the Side Effects of Depolan?
Like all opioid medications, Depolan (morphine) can cause side effects. The most common are constipation, nausea, drowsiness, and dizziness. The most serious potential side effect is respiratory depression, which can be life-threatening. Most side effects are dose-dependent and may improve with continued use, except constipation, which typically requires ongoing management.
Side effects of morphine are largely predictable based on its pharmacological profile as a mu-opioid receptor agonist. Most patients will experience at least some side effects, particularly during the initial phase of treatment or after dose increases. Understanding these effects helps patients and caregivers recognize what is expected, what can be managed with supportive measures, and what requires urgent medical attention.
Tolerance to many opioid side effects (such as nausea, sedation, and respiratory depression) develops within the first one to two weeks of regular use. However, tolerance to constipation develops slowly if at all, which is why preventive laxative therapy is recommended for essentially all patients receiving regular opioid treatment. The side effect frequencies listed below are based on clinical trial data and post-marketing surveillance from multiple regulatory agencies including the EMA and FDA.
Very Common (affects more than 1 in 10 patients)
- Constipation (often persistent throughout treatment)
- Nausea
- Drowsiness and sedation
- Dizziness
- Vomiting
Common (affects 1 in 10 to 1 in 100 patients)
- Headache
- Confusion or disorientation
- Dry mouth (xerostomia)
- Sweating (diaphoresis)
- Itching (pruritus)
- Loss of appetite (anorexia)
- Fatigue and weakness
- Abdominal pain or cramps
- Difficulty urinating (urinary retention)
- Orthostatic hypotension (dizziness when standing)
Uncommon (affects 1 in 100 to 1 in 1,000 patients)
- Respiratory depression (slow, shallow breathing)
- Hallucinations
- Mood changes (euphoria or dysphoria)
- Tremor or muscle rigidity
- Biliary spasm
- Skin rash
- Myoclonus (involuntary muscle jerks)
- Sleep disturbances (insomnia or excessive dreaming)
Rare (affects fewer than 1 in 1,000 patients)
- Anaphylaxis or severe allergic reaction
- Seizures
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
- Adrenal insufficiency
- Hypogonadism (with chronic use)
- Severe hypotension or bradycardia
When to Seek Immediate Medical Attention
Contact your doctor or emergency services immediately if you experience any of the following:
- Slow, shallow, or irregular breathing – or breathing stops
- Extreme drowsiness or difficulty staying awake
- Loss of consciousness or inability to be aroused
- Blue or purple discoloration of the lips, fingernails, or skin (cyanosis)
- Severe allergic reaction: swelling of the face, lips, tongue, or throat; difficulty breathing; widespread rash or hives
- Seizures or convulsions
- Chest pain or irregular heartbeat
Constipation: Start a laxative regimen (stimulant laxative such as senna, with or without a stool softener such as docusate) at the same time as opioid therapy begins. Increase fluid intake and dietary fiber. Constipation rarely resolves on its own during opioid treatment. Nausea: Often improves within 5–7 days. Antiemetics such as metoclopramide or ondansetron may help during the initial period. Drowsiness: Usually improves as tolerance develops. Avoid driving or operating machinery until you know how the medicine affects you.
How Should You Store Depolan?
Store Depolan at room temperature (below 25°C / 77°F), in the original packaging, protected from moisture and light. Keep out of reach of children and anyone who is not prescribed the medication. Due to its status as a controlled substance, Depolan must be stored securely to prevent theft, misuse, or accidental ingestion.
Proper storage of opioid medications is critically important not only for maintaining the drug's potency and effectiveness but also for preventing accidental exposure or intentional misuse by others. Morphine is a Schedule II controlled substance in many countries, reflecting its high potential for abuse and the severe consequences of unauthorized use.
Store Depolan tablets in their original blister pack or container. Do not transfer the tablets to another container. Avoid storing the medication in bathrooms or other areas with high humidity, as moisture can compromise the integrity of the extended-release coating. Do not freeze the tablets. Exposure to excessive heat (above 30°C / 86°F) may also affect the controlled-release properties of the formulation.
Keep Depolan in a secure location, ideally a locked cabinet or safe, inaccessible to children, visitors, and anyone not prescribed the medication. Accidental ingestion of even a single dose of morphine by a child can result in fatal respiratory depression. If a child accidentally takes Depolan, call emergency services immediately.
Disposal
Do not keep leftover or expired Depolan tablets. Unused morphine should be disposed of safely to prevent diversion or accidental exposure. Many pharmacies and hospitals offer take-back programs for unused medications. If no take-back option is available, consult your pharmacist about safe disposal methods. Do not flush morphine down the toilet or throw it in household waste unless specifically instructed to do so by local disposal guidelines.
What Does Depolan Contain?
Each Depolan extended-release tablet contains 10 mg of morphine sulfate as the active ingredient. The tablet also contains excipients that form the controlled-release matrix, including hydroxypropyl methylcellulose (hypromellose), microcrystalline cellulose, and other inactive ingredients.
The active pharmaceutical ingredient in Depolan is morphine sulfate pentahydrate, equivalent to 10 mg of morphine sulfate per tablet. Morphine sulfate is the sulfate salt form of morphine, an opiate alkaloid originally derived from the opium poppy (Papaver somniferum). In modern pharmaceutical manufacturing, morphine is produced either by extraction from opium or by semi-synthesis from thebaine, another opium alkaloid.
The inactive ingredients (excipients) in Depolan play essential roles in the tablet's function. The extended-release matrix typically consists of hydroxypropyl methylcellulose (hypromellose, HPMC), which forms a gel barrier around the tablet core when it contacts gastrointestinal fluid, controlling the rate at which morphine is released. Other common excipients include microcrystalline cellulose (a filler and binder), lactose monohydrate (a diluent), magnesium stearate (a lubricant to aid tablet pressing), and colloidal silicon dioxide (a glidant). The tablet may have a film coating containing materials such as polyethylene glycol, titanium dioxide, and possibly coloring agents.
Patients with known allergies or intolerances to any excipients (particularly lactose in patients with lactose intolerance or galactose malabsorption) should review the full list of ingredients with their pharmacist. The complete list of excipients can be found on the patient information leaflet included in the medication package.
Frequently Asked Questions About Depolan
Depolan (morphine sulfate extended-release) is used for the management of severe pain that requires continuous, around-the-clock opioid treatment. It is commonly prescribed for cancer-related pain and other chronic severe pain conditions where non-opioid analgesics and weaker opioids have proven insufficient. The extended-release formulation provides sustained pain relief over approximately 12 hours, allowing twice-daily dosing.
No. Depolan extended-release tablets must never be crushed, chewed, broken, or dissolved. The tablet is engineered to release morphine gradually over 12 hours. Destroying the controlled-release mechanism would cause the entire dose to be absorbed rapidly, potentially leading to a fatal overdose due to the sudden spike in blood morphine levels.
The most common side effects of Depolan include constipation (which affects the majority of patients and usually persists throughout treatment), nausea, drowsiness and sedation, dizziness, and vomiting. Constipation requires preventive management with laxatives. Most other side effects tend to improve as tolerance develops over the first one to two weeks, though patients should report any persistent or troublesome effects to their doctor.
Depolan contains morphine, a strong opioid that carries a risk of physical dependence, tolerance, and addiction (opioid use disorder). Physical dependence means that withdrawal symptoms will occur if the medication is stopped suddenly. When used as prescribed for legitimate pain under medical supervision, the risk of developing true addiction is lower than with recreational use. However, all patients on long-term opioid therapy should be regularly assessed for signs of misuse. Treatment should never be stopped abruptly – your doctor will taper the dose gradually when it is time to discontinue.
Depolan is an extended-release (depot) formulation that releases morphine gradually over approximately 12 hours, providing steady background pain control with twice-daily dosing. Immediate-release morphine provides rapid pain relief within 30–60 minutes but only lasts 4–6 hours, requiring more frequent dosing. Extended-release formulations like Depolan are best suited for continuous baseline pain, while immediate-release morphine is typically used for breakthrough pain episodes on top of the extended-release regimen.
If you miss a dose, take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Never take a double dose, as this can cause dangerous respiratory depression. If you frequently forget doses, consider setting reminders or alarms. Contact your doctor or pharmacist if you are unsure what to do.
References
- World Health Organization (WHO). WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: WHO; 2018. Updated 2023.
- European Medicines Agency (EMA). Summary of Product Characteristics: Morphine Sulfate Extended-Release Tablets. EMA; 2024.
- U.S. Food and Drug Administration (FDA). Prescribing Information: Morphine Sulfate Extended-Release Tablets. FDA; 2024.
- British National Formulary (BNF). Morphine: Indications, dose, contraindications, cautions, interactions, side effects. NICE Evidence Services; 2025.
- Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7(7):CD012592.
- Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–e68.
- Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of Postoperative Pain: A Clinical Practice Guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists. J Pain. 2016;17(2):131–157.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(No. RR-3):1–95.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- European Society for Medical Oncology (ESMO). Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv166–iv191.
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, a multidisciplinary group of licensed physicians, clinical pharmacologists, and pain medicine specialists. Our team follows the GRADE evidence framework and adheres to guidelines from the World Health Organization (WHO), European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), and the British National Formulary (BNF).
All medical content on iMedic is independently produced with no pharmaceutical company sponsorship or commercial funding. We maintain strict editorial independence to ensure that the information we provide is accurate, unbiased, and genuinely helpful to patients and caregivers.